Rosmorduc O, Chevreau C, Dielenseger P, Ederhy S, Goldwasser F, Grange J-D, Mortier L, Neidhardt-Berard M-E, Robert C, Scotté F, Seitz J-F
Service d'hépatologie, hôpital Saint-Antoine, 184, rue du Faubourg St-Antoine, 75012 Paris, France.
Gastroenterol Clin Biol. 2010 Mar;34(3):161-7. doi: 10.1016/j.gcb.2009.12.004. Epub 2010 Feb 23.
Therapeutic approaches of cancers have been recently improved by the development of targeted therapies. Amongst these new drugs, some anti-angiogenic molecules have been approved by either the EMEA or the Food and Drug Administration. Sorafenib, one of these inhibitors of angiogenesis, has been established as the standard of care for advanced hepatocellular and renal carcinoma. This paper reviews the safety profile of sorafenib and presents guidelines for the prevention and the treatment of the main side effects associated with this molecule.
近年来，靶向治疗的发展改善了癌症的治疗方法。在这些新药中，一些抗血管生成分子已获得欧洲药品管理局（EMEA）或美国食品药品监督管理局（FDA）的批准。索拉非尼作为这些血管生成抑制剂之一，已被确立为晚期肝细胞癌和肾癌的治疗标准。本文综述了索拉非尼的安全性概况，并提出了预防和治疗与该分子相关的主要副作用的指南。
